189 related articles for article (PubMed ID: 9135090)
1. Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid.
Alexi T; Venero JL; Hefti F
Neuroscience; 1997 May; 78(1):73-86. PubMed ID: 9135090
[TBL] [Abstract][Full Text] [Related]
2. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
Hughes PE; Alexi T; Williams CE; Clark RG; Gluckman PD
Neuroscience; 1999; 92(1):197-209. PubMed ID: 10392842
[TBL] [Abstract][Full Text] [Related]
3. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
[TBL] [Abstract][Full Text] [Related]
4. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease.
Araujo DM; Hilt DC
Neuroscience; 1997 Dec; 81(4):1099-110. PubMed ID: 9330371
[TBL] [Abstract][Full Text] [Related]
5. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA.
Venero JL; Beck KD; Hefti F
Neuroscience; 1994 Jul; 61(2):257-68. PubMed ID: 7969907
[TBL] [Abstract][Full Text] [Related]
6. Antioxidant treatment protects striatal neurons against excitotoxic insults.
Nakao N; Grasbon-Frodl EM; Widner H; Brundin P
Neuroscience; 1996 Jul; 73(1):185-200. PubMed ID: 8783241
[TBL] [Abstract][Full Text] [Related]
7. Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage.
Pérez-Navarro E; Arenas E; Reiriz J; Calvo N; Alberch J
Neuroscience; 1996 Nov; 75(2):345-52. PubMed ID: 8931001
[TBL] [Abstract][Full Text] [Related]
8. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease.
Pérez-Navarro E; Akerud P; Marco S; Canals JM; Tolosa E; Arenas E; Alberch J
Neuroscience; 2000; 98(1):89-96. PubMed ID: 10858615
[TBL] [Abstract][Full Text] [Related]
9. Evidence for bidirectional changes in nitric oxide synthase activity in the rat striatum after excitotoxically (quinolinic acid) induced degeneration.
Schmidt W; Wolf G; Calka J; Schmidt HH
Neuroscience; 1995 Jul; 67(2):345-56. PubMed ID: 7545791
[TBL] [Abstract][Full Text] [Related]
10. The effect of nitric oxide synthase inhibition on quinolinic acid toxicity in the rat striatum.
MacKenzie GM; Jenner P; Marsden CD
Neuroscience; 1995 Jul; 67(2):357-71. PubMed ID: 7545792
[TBL] [Abstract][Full Text] [Related]
11. Neurotrophin-4/5 selectively protects nigral calbindin-containing neurons in rats with medial forebrain bundle transections.
Alexi T; Hefti F
Neuroscience; 1996 Jun; 72(4):911-21. PubMed ID: 8735219
[TBL] [Abstract][Full Text] [Related]
12. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease.
Pérez-Navarro E; Canudas AM; Akerund P; Alberch J; Arenas E
J Neurochem; 2000 Nov; 75(5):2190-9. PubMed ID: 11183872
[TBL] [Abstract][Full Text] [Related]
13. Chronic intrastriatal dialytic administration of quinolinic acid produces selective neural degeneration.
Bazzett TJ; Becker JB; Kaatz KW; Albin RL
Exp Neurol; 1993 Apr; 120(2):177-85. PubMed ID: 8387931
[TBL] [Abstract][Full Text] [Related]
14. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.
Huang Q; Zhou D; Sapp E; Aizawa H; Ge P; Bird ED; Vonsattel JP; DiFiglia M
Neuroscience; 1995 Mar; 65(2):397-407. PubMed ID: 7777157
[TBL] [Abstract][Full Text] [Related]
15. Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease.
Susel Z; Engber TM; Kuo S; Chase TN
Neurosci Lett; 1991 Jan; 121(1-2):234-8. PubMed ID: 1826944
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of the neuroprotective properties of competitive and uncompetitive N-methyl-D-aspartate receptor antagonists in vivo: implications for the process of excitotoxic degeneration and its therapy.
Massieu L; Thedinga KH; McVey M; Fagg GE
Neuroscience; 1993 Aug; 55(4):883-92. PubMed ID: 7694181
[TBL] [Abstract][Full Text] [Related]
17. Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid.
Nakao N; Brundin P
Neuroscience; 1997 Feb; 76(3):749-61. PubMed ID: 9135048
[TBL] [Abstract][Full Text] [Related]
18. Nerve growth factor and basic fibroblast growth factor protect cholinergic neurons against quinolinic acid excitotoxicity in rat neostriatum.
Pérez-Navarro E; Alberch J; Arenas E; Calvo N; Marsal J
Eur J Neurosci; 1994 May; 6(5):706-11. PubMed ID: 8075815
[TBL] [Abstract][Full Text] [Related]
19. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo.
Pérez-Navarro E; Alberch J; Neveu I; Arenas E
Neuroscience; 1999; 91(4):1257-64. PubMed ID: 10391433
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome.
Bensadoun JC; de Almeida LP; Dréano M; Aebischer P; Déglon N
Eur J Neurosci; 2001 Dec; 14(11):1753-61. PubMed ID: 11860469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
